FDA approves Lilly's oral SERD combo for second-line breast cancer therapy
RegulatoryapprovedInluriyoPositive
AI Analysis
Summary
The FDA approved Eli Lilly's oral selective estrogen receptor degrader (SERD) combination therapy Inluriyo for second-line treatment of metastatic breast cancer. This represents a significant regulatory milestone for Lilly's oncology portfolio.
Outcome Details
FDA approved oral SERD combination regimen for second-line metastatic breast cancer
Importance:9/10
Sentiment:
0.90
FDA approvaloncologybreast cancerSERDoral therapy
Related Companies
Read the original article
Published by Endpoints News on September 18, 2026 7:32 PM